article thumbnail

Madrigal wins FDA approval of first drug for MASH

BioPharma Drive: Drug Pricing

But its sales potential is unclear, and competition could emerge from popular weight loss drugs. Rezdiffra’s clearance is a turning point in the fight against the liver disease.

article thumbnail

FDA Approved Oncology Drugs 2023

Crown Bioscience

In a significant development, the US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 55 new drugs in 2023.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Approves New Drug to Treat Alzheimer's, Kisunla

Drugs.com

TUESDAY, July 2, 2024 -- A new drug to treat Alzheimer's disease was approved by the U.S. Food and Drug Administration on Tuesday. In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early.

article thumbnail

FDA Approves New Drug to Treat Alzheimer's

Drugs.com

TUESDAY, July 2, 2024 -- A new drug to treat Alzheimer's disease was approved by the U.S. Food and Drug Administration on Tuesday.In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early.

article thumbnail

FDA Approves New Drug for Deadly Lung Cancer, Imdelltra

Drugs.com

Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer. FRIDAY, MAY 17, 2024 -- The U.S. Importantly, tarlatamab (Imdelltra) is only for patients who have exhausted all other.

article thumbnail

The Regulatory Maze: How Generic Drugs Navigate FDA Approval

Drug Patent Watch

In the high-stakes world of pharmaceuticals, generic drugs have become the unsung heroes of healthcare accessibility. These cost-effective alternatives to […] Source

article thumbnail

FDA approves Ascendis drug for rare endocrine condition

BioPharma Drive: Drug Pricing

The clearance of Yorvipath for hypoparathyroidism was some time coming for Ascendis, which had resubmitted after receiving a rejection last year.